Eli Lilly returns to Indianapolis after a week of Washington influence and Boston business

Eli Lilly flew from Boston Logan International Airport to Indianapolis International Airport on May 21, arriving just before 10 p.m. local time after a swift two-hour Gulfstream G500 hop. The jet, N307EL, is one of three G500s operated by the Indianapolis-based drugmaker.

The flight lands in Indianapolis the same week the company is riding a wave of news from the FDA's 50-day approval of its obesity pill Foundayo (orforglipron), per Lilly's own Q1 earnings report on April 30. CEO Dave Ricks spent much of the spring shuttling between Washington and New York; Lilly jets touched DC-area airports at least five times in September alone, according to an Endpoints News analysis, and Ricks was present at an April 30 White House event with President Trump. The Boston leg likely involved meetings in the region's biotech cluster, a common stop on the executive circuit.

Recent flight data show N307EL cycling through Washington, New York, and Chicago before returning to base. The pattern reflects a company in constant motion: lobbying over Medicare GLP-1 coverage, launching the first oral weight-loss pill without food restrictions, and raising 2026 revenue guidance to $85 billion. For a pharma giant, there is no off-season — only the next destination.